Guidelines for the use of clozapine in individuals with developmental disabilities

Research in Developmental Disabilities

Volumn 27, Issue 3, 2006, Pages 309-336

  Sabaawi, Mohamed ^a   Singh, Nirbhay N ^b   de Leon, Jose ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ONE RESEARCH INSTITUTE   (United States)

Author keywords

Antipsychotic medication; Clozapine; Clozapine guidelines; Individuals with developmental disabilities

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZATROPINE; BENZATROPINE MESILATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CLOZAPINE; CORTICOSTEROID; ENEMA; EPHEDRINE; FLUDROCORTISONE; GABAPENTIN; IPRATROPIUM BROMIDE; LAMOTRIGINE; LAXATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NORCLOZAPINE; OXYBUTYNIN; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE; AGGRESSION; AGRANULOCYTOSIS; AKATHISIA; ARTICLE; ATAXIA; AUTOMUTILATION; BEHAVIOR; BLOOD ANALYSIS; BLOOD CELL COUNT; BLOOD PRESSURE MONITORING; BLOOD TOXICITY; BODY WEIGHT; BODY WEIGHT DISORDER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; COOPERATION; CREATINE KINASE BLOOD LEVEL; DECISION MAKING; DELIRIUM; DESTRUCTION; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DIET; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; DYSPNEA; ECG ABNORMALITY; EOSINOPHILIA; EPIDEMIOLOGICAL DATA; EXERCISE; EXPERIENCE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GRAND MAL SEIZURE; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HEARTBURN; HEREDITY; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSALIVATION; HYPERTENSION; HYPERTHERMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; IMPOTENCE; INFECTION; INFORMED CONSENT; LABORATORY TEST; LETHARGY; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPIDOSIS; LITERATURE; LIVER FUNCTION TEST; LIVER TOXICITY; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; METABOLIC DISORDER; MOTOR DYSFUNCTION; MOUTH TEMPERATURE; MYOCARDITIS; MYOCLONUS SEIZURE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; NOCTURNAL ENURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATION; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARKINSONISM; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SELECTION; POLYDIPSIA; PRACTICE GUIDELINE; PRIAPISM; PULSE RATE; QT PROLONGATION; RESPIRATORY ARREST; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SLURRED SPEECH; SMOKING; ST SEGMENT; STEADY STATE; SYNCOPE; TACHYCARDIA; TARDIVE DYSKINESIA; THORAX PAIN; TONIC CLONIC SEIZURE; TOXIC HEPATITIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TREMOR; URINE INCONTINENCE; VISUAL DISORDER; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHILD; CLINICAL TRIALS; CLOZAPINE; DEVELOPMENTAL DISABILITIES; FEMALE; GUIDELINES; HUMANS; MALE;

EID: 33646029721     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2005.05.002     Document Type: Article

References (111)

1. Abdel-Razzak Z., Loyer P., Fautrel A., Gautier J.C., Corcos L., Turlin B., et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Molecular Pharmacology 44 (1993) 707-715
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 156 (1999) 1686-1696
3. Alvir J.M.J., Lieberman J.A., Safferman A.Z., Schwimmer J.L., and Schaff J.A. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States. New England Journal of Medicine 329 (1993) 162-167
4. Antelo R.E., Stanilla J.K., and Martin-Llonch N. Myoclonic seizures and "leg folding" phenomena with clozapine therapy: Report of two cases. Biological Psychiatry 36 (1994) 759-762
5. Antonacci D.J., and de Groot C.M. Clozapine treatment in a population of adults with mental retardation. Journal of Clinical Psychiatry 61 (2000) 22-25
6. Bak T.H., Bauer M., Scaub R.T., Hellweg R., and Reischics F.M. Myclonus in patients treated with clozapine: A case series. Journal of Clinical Psychiatry 53 (1995) 329-330
7. Baldessarini R.J., and Frankenburg F.R. A novel antipsychotic agent. New England Journal of Medicine 324 (1991) 746-754
8. Barclay L. Clozapine reduces suicide attempts in schizophrenic patients. Archives of General Psychiatry 60 (2003) 82-91
9. Bender S., and Eap C.B. Very high cytochrome P4501A2 activity and non-response to clozapine (letter). Archives of General Psychiatry 35 (1998) 1048-1050
10. Benedetti F., Sforzini L., Colombo C., Maffei C., and Smeraldi E. Low dose clozapine in acute and continuation treatment of severe personality disorder. Journal of Clinical Psychiatry 59 (1998) 103-107
11. Bertilsson L., Carrillo J.A., Dahl M., Llerena A., Alm C., Bondesson U., et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology 38 (1994) 471-473
12. Bremner A., and Regan A. Polydipsia and water intoxication in a mental handicap hospital. British Journal of Psychiatry 158 (1991) 244-250
13. Buzan R., Dubovsky S.L., Firestone D., and Dal Pozzo E. Use of clozapine in ten mentally retarded adults. Journal of Neuropsychiatry 10 (1998) 93-95
14. Canuso C.M., and Goldman M.B. Clozapine restores water balance in schizophrenic patients with polydipsia-hyponatremia syndrome. Journal of Neuropsychiatry and Clinical Neurosciences 11 (1999) 86-90
15. Centorrino F., Baldessarini R.J., Kando J.C., Frankenburg F.R., Volpicelli S.A., Puopolo P.R., et al. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry 151 (1994) 123-125
16. Chengappa K.N., Ebeling T., Kang J.S., Levine J., and Parepally H. Clozapine reduces self-mutilation and aggression in psychotic patients with borderline personality disorder. Journal of Clinical Psychiatry 60 (1999) 477-484
17. Choc M.G., Hsuan F., Honigfeld G., Robinson W.T., Ereshefsky L., Crismon M.L., et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharmacy Research 4 (1987) 402-405
18. Cobb C.D., Anderson C.B., and Seidel D.R. Possible interaction between clozapine and lorazepam (letter). American Journal of Psychiatry 148 (1991) 1606-1607
19. Cohen S.A., and Underwood M.T. The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry 55 (1994) 440-444
20. Conley R.R. Optimizing treatment with clozapine. Journal of Clinical Psychiatry 59 (1998) 44-48
21. Conley R.R., and Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin 23 (1997) 663-674
22. Cooke C., and de Leon J. Adding other antipsychotics to clozapine (letter). Journal of Clinical Psychiatry 60 (1999) 710
23. Deb S., Bramble D., Drybala G., Boyle A., and Bruce J. Polydipsia amongst adults with a learning disability in an institution. Journal of Intellectual Disability Research 38 (1994) 359-367
24. de Leon J. Polydipsia: A study in a long-term psychiatric unit. European Archives of Psychiatry and Clinical Neurosciences 253 (2003) 37-39
25. de Leon J. Glucuronidation enzyme genes and psychiatry. International Journal of Neuropsychopharmacology 6 (2003) 57-72
26. de Leon J. Atypical antipsychotic dosing: The effect of smoking and caffeine. Psychiatric Services 55 (2004) 491-493
27. de Leon J. Atypical antipsychotic dosing: The effect of co-medication with anticonvulsants. Psychiatric Services 55 (2004) 125-128
28. de Leon J. Respiratory infections rather than antibiotics may increase clozapine levels: A critical review of the literature (letter). Journal of Clinical Psychiatry 65 (2004) 1144-1145
29. de Leon J., and Diaz F.J. Serious respiratory infections can increase clozapine levels and contribute to side effects: A case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27 (2003) 1059-1063
30. de Leon J., Diaz F.J., Rogers T.J., Browne D., Dinsmore L., Ghosheh O., et al. A pilot study of plasma caffeine concentrations in a US sample of smokers and non-smokers volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27 (2003) 165-171
31. de Leon J., Henighan V., Stanilla J.K., and Simpson G.M. Clozapine levels after clozapine discontinuation (letter). Journal of Clinical Psychopharmacology 16 (1996) 193-194
32. de Leon J., Odom-White A., Josiassen R.C., Diaz F.J., Cooper T.B., and Simpson G.M. Serum muscarinic activity during clozapine treatment. Journal of Clinical Psychopharmacology 23 (2003) 336-341
33. de Leon J., Stanilla J.K., White A.O., and Simpson G.M. Anticholinergics to treat clozapine withdrawal (letter). Journal of Clinical Psychiatry 55 (1994) 119-120
34. de Leon J., Verghese C., Stanilla J., Lawrence T., and Simpson G.M. Treatment of polydipsia and hyponatremia in psychiatric patients: Can clozapine be a new option?. Neuropsychopharmacology 13 (1995) 133-138
35. Finkel M., and Schwimmer J.L. Clozapine a novel antipsychotic agent (letter). New England Journal of Medicine 325 (1991) 518-519
36. Food and Drug Administration. Class labeling change for atypical antipsychotics (2003), Food and Drug Administration, Washington, DC
37. Friedman J.H., and Lannon M.C. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 39 (1989) 1219-1221
38. Gaftanyuk O., and Trestman R.L. Scopolamine patch for clozapine-induced sialorrhea (letter). Psychiatric Services 55 (2004) 318
39. Ghaeli P., and Dufresne R.L. Serum triglyceride levels in patients treated with clozapine. American Journal of Health-Systems Pharmacy 53 (1996) 2079-2081
40. Gianfrancesco F.D., Grogg A.L., Mahmoud R.A., Wang R., and Nasrallah H.A. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type II diabetes: Findings from a large health plan database. Journal of Clinical Psychiatry 63 (2002) 920-930
41. Gobbi G. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. Journal of Psychiatry and Neuroscience 26 (2001) 340-341
42. Goldman M.B., and Luchins D.J. Prevention of episodic water intoxication with target weight procedure. American Journal of Psychiatry 144 (1991) 365-366
43. Gouzoulis E., Ozdaglar A., and Kasper J. Myoclonic seizures followed by grand mal seizures during clozapine treatment (letter). American Journal of Psychiatry 150 (1993) 1128
44. Grabowski J. Clonidine treatment of clozapine-induced hypersalivation (letter). Journal of Clinical Psychopharmacology 12 (1992) 69-70
45. Grace J., Bellus S.B., Raulin M.L., Herz M.I., Priest B.L., Brenner V., et al. Long term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatric Services 47 (1996) 41-45
46. Green A.L., Zimmet S.V., Strous R.D., and Schildkraut J.J. Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harvard Review of Psychiatry 6 (1999) 287-296
47. Hagg S., Joelsson L., Mjorndal T., Spigset O., Oja G., and Dahlquist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated conventional depot neuroleptic medications. Journal of Clinical Psychiatry 59 (1998) 294-299
48. Hagg S., Spigset O., Mjorndal T., Granberg K., Persbo-Lundqvist G., and Dahlqvist R. Absence of interaction between erythromycin and a single dose of clozapine. European Journal of Clinical Pharmacology 55 (1999) 221-226
49. Hammock R., Levine W.R., and Schroeder S.R. Brief report: Effects of clozapine on self-injurious behavior of two risperidone non-responders with mental retardation. Journal of Autism and Developmental Disorder 31 (2001) 109-113
50. Hammock R.G., Schroeder S.R., and Levine W.R. Effects of clozapine on self-injurious behavior. Journal of Autism and Developmental Disorders 25 (1995) 611-627
51. Hasegawa M., Gutierrez-Esteinou R., Way L., and Meltzer H.Y. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. Journal of Clinical Psychopharmacology 13 (1993) 383-390
52. Hayfron-Benjamin J., Peters C.A., and Woodhouse R.A. A demographic study of polydipsia in an institution for the intellectually disabled. Canadian Journal of Psychiatry 41 (1996) 519-522
53. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five-year naturalistic study. American Journal of Psychiatry 157 (2000) 975-981
54. Hiemke C., Weigmann H., Harter S., Dahmen N., Wetzel H., and Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine (letter). Journal of Clinical Psychopharmacology 14 (1994) 279-281
55. Iqbal M.I., Rahman A., Husain Z., Mahmud S.Z., Ryan W.G., and Feldman J.M. Clozapine: A clinical review of adverse effects and management. Annals of Clinical Psychiatry 15 (2003) 33-48
56. Kane J., Honigfeld G., Singer J., and Meltzer H.Y. Clozapine for the treatment resistant schizophrenic: A double blind comparison with chlorpromazine (Clozaril collaborative study). Archives of General Psychiatry 45 (1988) 789-796
57. Kilian J.G., Kerr K., Lawrence C., and Celermajer D.S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 354 (1999) 1841-1845
58. Klimke A., and Klieser E. Sudden death after intravenous application of lorazepam in a patient treated with clozapine (letter). American Journal of Psychiatry 151 (1994) 780
59. Kronig M.H., Munne R.H., Szymanski S., Safferman A.Z., Pollack S., Cooper T., et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. American Journal of Psychiatry 152 (1995) 179-182
60. Kurz M., Hummer M., Kemmler G., Kurzthaler I., Saria A., and Fleischhacker W.W. Long-term pharmacokinetics of clozapine. British Journal of Psychiatry 173 (1998) 341-344
61. Lebovitz H.L. Diagnosis, classification and pathogenesis of diabetes mellitus. Journal of Clinical Psychiatry 62 Suppl. 27 (2001) 5-9
62. Lieberman J.A., Yunis J., Egea E., Canoso R.T., Kane J.M., and Yunis E.J. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry 47 (1990) 945-948
63. Marder S.R., and Wirshing D.A. Clozapine. In: Schatzberg C.B., and Nemeroff C.B. (Eds). The American psychiatric publishing textbook of psychopharmacology (2004), American Psychiatric Publishing, Washington, DC 443-456
64. McCarthy R.H. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 27 (1994) 210-211
65. McElroy S.L. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder and schizophrenia. Journal of Clinical Psychiatry 52 (1991) 4111-4114
66. Meltzer H.Y. Dimensions of outcome with clozapine. British Journal of Psychiatry 160 (1992) 46-53
67. Meltzer H.Y., Alphs L., Green A.I., Alatamura A.C., Anand R., Bertoldi A., et al. Clozapine treatment for suicidality in schizophrenia. Archives of General Psychiatry 60 (2003) 82-90
68. Meltzer H.Y., Burnett S., Bastani B., and Ramirez L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry 41 (1990) 892-897
69. Meyer J.M. Effects of atypical antipsychotics on weight and serum lipid levels. Journal of Clinical Psychiatry 62 (2001) 27-34
70. Michals M.L., Crismon M.L., Roberts S., and Childs A. Clozapine response and adverse effects in nine brain injured patients. Journal of Clinical Psychopharmacology 13 (1993) 198-203
71. Miller D.D. Effect of phenytoin on plasma clozapine concentrations in two patients (letter). Journal of Clinical Psychiatry 52 (1991) 23-25
72. Miller D.D. Review and management of clozapine side effects. Journal of Clinical Psychiatry 61 (2000) 14-19
73. Miller A.L., Hall C.S., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., et al. The Texas medication algorithm project (TMAP)-antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry 65 (2004) 500-508
74. Novartis Pharmaceutical Corporation. Clozapine: Patient management handbook (1997), Novartis Pharmaceutical Corporation, East Hanover, NJ
75. Novartis Pharmaceutical Corporation. Letter (2002), Novartis Pharmaceutical Corporation, East Hanover, NJ
76. Novartis Pharmaceutical Corporation. Revised package insert (2003), Novartis Pharmaceutical Corporation, East Hanover, NJ
77. Novartis Pharmaceutical Corporation. Clozaril National Registry (CNR): Participation guide (2004), Novartis Pharmaceutical Corporation, East Hanover, NJ
78. Pary R.J. Clozapine in three individuals with mild mental retardation and treatment refractory psychiatric disorders. Mental Retardation 32 (1994) 323-327
79. Perry P.J., Bever K.A., Arndt S., and Combs M.D. Relationship between patient variables and plasma clozapine concentrations: A dosing nomogram. Biological Psychiatry 44 (1998) 733-738
80. Perry P.J., Miller D.D., Arndt S.V., and Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenia patients. American Journal of Psychiatry 148 (1991) 231-235
81. Pinninti N.R., and de Leon J. Interaction of sertraline with clozapine (letter). Journal of Clinical Psychopharmacology 17 (1997) 119-120
82. Potkin S.G., Bera R., Gulasekaram B., Costa J., Hayes S., Jin Y., et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry 55 (1994) 133-136
83. Raaska K., and Neuvonen P.J. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: A study in patients with schizophrenia. European Journal of Clinical Pharmacology 56 (2000) 585-589
84. Reinstein M.J., Sirotovskaya L.A., Chasanov M.A., and Jones L.E. Comparative efficacy and tolerability of benztropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clinical Drug Investigation 17 (1999) 97-102
85. Rostami-Hodjegan A., Amin A.M., Spencer E.P., Leonnard M.S., Tucker G.T., and Flanagan R.J. Influence of dose, cigarette smoking, age sex and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. Journal of Clinical Psychopharmacology 24 (2004) 70-78
86. Rush A.J., and Frances A. Expert Consensus Guidelines Series: Treatment of psychiatric and behavioral problems in mental retardation. American Journal of Mental Retardation 105 (2000) 159-228
87. Safferman A., Lieberman J.A., Kane J.M., Szymanski S., and Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 17 (1991) 247-261
88. Sajatovic M., Ramirez L.F., Kenny J.T., and Meltzer H.Y. The use of clozapine in borderline-intellectual functioning and mentally retarded schizophrenic patients. Comprehensive Psychiatry 35 (1994) 29-33
89. Schroeder S.R., Hammock R., Mullick J.A., Rojhan J., Walson P., Fernald W., et al. Clinical trials of D1 and D2 dopamine modulating drugs and self-injury. Mental Retardation and Developmental Disabilities Research Reviews 1 (1995) 120-129
90. Simpson G.M., and Cooper T.A. Clozapine plasma levels and convulsions. American Journal of Psychiatry 135 (1978) 99-100
91. Simpson G.M., Josiassen R.C., Stanilla J.K., de Leon J., Nair C., Abraham G., et al. Double-blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry 156 (1999) 1744-1750
92. Singer K., and Law S. A double blind comparison of clozapine and chlorpromazine in schizophrenia of acute symptomatology. Journal of International Medical Research 2 (1974) 433-435
93. Skogh E., Bengtsson F., and Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Therapeutic Drug Monitoring 21 (1994) 580-582
94. Spivak B., Mester R., Abesgaus J., Wittenberg N., Adlersberg S., Gonen N., et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism and chronic akasthisia in schizophrenic patients. Journal of Clinical Psychiatry 58 (1997) 318-322
95. Sprague R.L., and Kalachnik J.E. Reliability, validity, and a total score cutoff for the Dyskinesia Identification System: Condensed User Scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacology Bulletin 27 (1991) 51-58
96. Stanilla J.K., de Leon J., and Simpson G.M. Clozapine withdrawal resulting in delirium with psychosis: A report of three cases. Journal of Clinical Psychiatry 58 (1997) 252-255
97. Suppes T., Phillips K.A., and Judd C.R. Clozapine treatment of non-psychotic rapid cycling bipolar disorder: A report of three cases. Biological Psychiatry 36 (1994) 338-340
98. Szymanski S., Lieberman J.A., Picou D., Masiar S., and Cooper T. A case report of cimetidine induced clozapine toxicity (letter). Journal of Clinical Psychiatry 52 (1991) 21-22
99. Tandon R., Goldman R., DeQuardro J.R., Goldman M., Perez M., and Jibson M. Positive and negative symptoms covary during clozapine treatment in schizophrenia. Journal of Psychiatric Research 27 (1993) 341-347
100. The Parkinson's Study Group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. New England Journal of Medicine 340 (1999) 757-763
101. Townsend M.H., and Baier M.H. Clozapine-induced sialorrhea treated with sublingual ipratropium spray: A case series (letter). Journal of Clinical Psychopharmacology 24 (2004) 98-100
102. VenderZwaag C., McGee M., McEvoy J.P., Freudenreich O., Wilson W.H., and Cooper T.B. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. American Journal of Psychiatry 153 (1996) 1579-1584
103. Verghese C., Abraham G., Nair C., Stanilla J.K., de Leon J., Phillips M.I., et al. Absence of changes in antidiuretic hormone, angiotensin II, and atrial natriuretic peptide with clozapine treatment of polydipsia-hyponatremia: Two case reports. Journal of Clinical Psychiatry 59 (1998) 415-419
104. Verghese C., de Leon J., and Josiassen R. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia. Schizophrenia Bulletin 22 (1996) 455-464
105. Vistisen K., Loft S., and Poulsen H.E. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: Effect of smoking, broccoli and exercise. Advances in Experimental Medicine and Biology 283 (1991) 407-411
106. Wahlbeck K., Cheine M., Essalie A., and Adams C. Evidence for clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. American Journal of Psychiatry 156 (1999) 990-999
107. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., and Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. Journal of Clinical Psychiatry 63 (2002) 856-865
108. Wooltorton E. Antipsychotic clozapine (clozaril): Myocarditis and cardiovascular toxicity. Canadian Medical Association Journal 116 (2002) 1185-1186
109. Young C.R., Bowers M.B., and Mazure C.M. Management of the adverse effects of clozapine. Schizophrenia Bulletin 24 (1998) 381-390
110. Zarate Jr. C.A., Tohen M., and Baldessarini R.J. Clozapine in severe mood disorder. Journal of Clinical Psychiatry 56 (1995) 411-417
111. Zullino D.F., Delessert D., Eap C.B., Preisig M., and Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. International Clinical Psychopharmacology 17 (2002) 141-143